

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7905105

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT
EFFECTIVE DATE:	12/13/2021

CONVEYING PARTY DATA

Name	Execution Date
ENGMAB BETA HOLDINGS LLC	12/13/2021

RECEIVING PARTY DATA

Name:	BRISTOL-MYERS SQUIBB COMPANY
Street Address:	ROUTE 206 AND PROVINCE LINE ROAD
City:	PRINCETON
State/Country:	NEW JERSEY
Postal Code:	08543

PROPERTY NUMBERS Total: 14

Property Type	Number
Application Number:	63077233
Application Number:	17089433
Application Number:	15945554
Application Number:	14764967
Application Number:	14764968
Application Number:	15501620
Application Number:	15747385
Application Number:	16821895
Application Number:	16997565
Application Number:	16773927
Application Number:	15517296
Application Number:	16346771
Application Number:	17304683
Application Number:	17304702

CORRESPONDENCE DATA

Fax Number: (716)626-0366

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (716) 239-4300

Email: esimpson@colsonlawgroup.com
Correspondent Name: ELLEN S. SIMPSON
Address Line 1: 5555 MAIN STREET
Address Line 4: WILLIAMSVILLE, NEW YORK 14221

ATTORNEY DOCKET NUMBER:	BPA0015
NAME OF SUBMITTER:	ELLEN S. SIMPSON
SIGNATURE:	/Ellen S. Simpson/
DATE SIGNED:	04/17/2023

Total Attachments: 27

source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page1.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page2.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page3.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page4.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page5.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page6.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page7.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page8.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page9.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page10.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page11.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page12.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page13.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page14.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page15.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page16.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page17.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page18.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page19.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page20.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page21.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page22.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page23.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page24.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page25.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page26.tif
source=Conf. DoA_EngMab Holdings LLC to Bristol-Myers Squibb Company (13.12.2021)#page27.tif



PATENT ASSIGNMENT

This PATENT ASSIGNMENT (this “*Assignment*”), effective as of December 13, 2021 (the “*Effective Date*”), is made by and between EngMab Beta Holdings LLC, a limited liability company organized under the laws of Delaware (“*Assignor*”), and Bristol-Myers Squibb Company, a corporation organized under the laws of Delaware (“*Assignee*”). Assignee and Assignor are sometimes herein each referred to as a “*Party*” and collectively as the “*Parties*.” Capitalized terms used herein but not otherwise defined herein shall have the meanings set forth in the Assignment and Assumption Agreement (defined below).

WHEREAS, Assignor and Assignee have entered into that certain Assignment and Assumption Agreement, dated as of the Effective Date (as may be amended or restated from time to time, the “*Assignment and Assumption Agreement*”), pursuant to which, among other things, Assignor agreed to assign and transfer to Assignee the Transferred Intellectual Property (as defined in the Assignment and Assumption Agreement), as more fully described in the Assignment and Assumption Agreement, on the terms and subject to the conditions set forth in the Assignment and Assumption Agreement;

WHEREAS, the Transferred Intellectual Property includes, without limitation, the Patents (as defined in the Assignment and Assumption Agreement) set forth on Annex A hereto (collectively, the “*Transferred Patents*”); and

WHEREAS, Assignor and Assignee now desire to enter into this Assignment to evidence the sale, assignment, transfer and delivery to Assignee of the Transferred Patents;

NOW THEREFORE, for good and valuable consideration, including the consideration set forth in the Assignment and Assumption Agreement, the receipt and sufficiency of which is hereby acknowledged, Assignor and Assignee hereby agree as follows:

1. Assignment. Assignor has assigned and transferred to Assignee and hereby assigns and transfers to Assignee, and Assignee has accepted, acquired, and assumed from Assignor and hereby accepts, acquires, and assumes from Assignor, all rights and interests of Assignor in and to the Transferred Patents, for the United States and for all foreign countries, including, without limitation, any reissues, divisions, continuations, continuations-in-part, extensions, re-examinations and foreign equivalents thereof, all inventions disclosed therein and improvements thereto, all rights to claim priority thereto or therefrom, and all rights therein provided by international treaties and conventions, together with the rights to all associated income, royalties, damages or payments accrued, due or payable with respect to the foregoing, including without limitation all claims for damages by reason of past, present or future infringement or other unauthorized use of the Transferred Patents, with the right to sue for, and collect the same, in each case, for Assignee’s own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made.

2. No Warranties. Except as expressly provided in the Assignment and Assumption Agreement, Assignor makes no warranties, express or implied, with respect to the Transferred Patents.

3. Recordal. Assignor hereby authorizes and requests the Commissioner of Patents of the United States, and any other official of any applicable Governmental Authority, to record this Assignment and to issue any and all registrations from any and all applications for registration included in the Transferred Patents to and in the name of Assignee.

4. Further Assurances. Assignor shall, at the cost and expense of Assignee, timely execute and deliver any additional documents and perform such additional acts necessary or desirable to record and perfect the interest of Assignee in and to the Transferred Patents.

5. Interpretation. This Assignment is intended to implement the provisions of the Assignment and Assumption Agreement, is expressly subject to the terms and conditions thereof, and shall not be construed to enhance, extend or limit the representations and warranties, rights, obligations or remedies of any party thereunder. In case of any conflict or inconsistency between the terms and conditions of this Assignment and the terms and conditions of the Assignment and Assumption Agreement, the terms and conditions of the Assignment and Assumption Agreement shall govern.

6. Amendment. Except as otherwise provided herein, no amendment, modification or supplement of any provision of this Assignment shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party.

7. Waiver. No provision of this Assignment shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party.

8. Counterparts, Facsimile Signatures. This Assignment may be executed in two (2) or more counterparts and such counterparts taken together shall constitute one and the same agreement. This Agreement may be signed in any manner that clearly evidences the Parties' intent to be bound, including via faxed, imaged, portable document format (pdf), electronic or digital signatures and such signature shall be deemed to be and shall be as effective as an original signature.

9. Descriptive Headings. The descriptive headings of this Assignment are for convenience only, and shall be of no force or effect in construing or interpreting any of the provisions of this Assignment.

10. Governing Law. This Assignment shall be governed and construed in accordance with the laws of the State of New York, without giving effect to any choice of law provisions thereof that would result in the application of the law of any jurisdiction other than New York. Each Party hereby submits itself for the purpose of this Assignment and any controversy arising hereunder to the exclusive jurisdiction of the state and federal courts located in the State of New York, and any courts of appeal therefrom, and waives any objection on the grounds of lack of jurisdiction (including, without limitation, venue) to the exercise of such jurisdiction over it by any such courts.

11. Severability. If any provision hereof should be held invalid, illegal or unenforceable in any respect in any jurisdiction, the Parties hereto shall substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions which valid provisions in their

economic effect are sufficiently similar to the invalid, illegal or unenforceable provisions that it can be reasonably assumed that the Parties would have entered into this Assignment with such valid provisions. In case such valid provisions cannot be agreed upon, the invalid, illegal or unenforceable provisions of this Assignment shall not affect the validity of this Assignment as a whole, unless the invalid, illegal or unenforceable provisions are of such essential importance to this Assignment that it is to be reasonably assumed that the Parties would not have entered into this Assignment without the invalid, illegal or unenforceable provisions.


12. Independent Contractors. The relationship between the Parties created by this Assignment is one of independent contractors and no Party shall have the power or authority to bind or obligate the others except as expressly set forth in this Assignment.

13. Expenses. Unless otherwise provided herein, all costs and expenses incurred in connection with this Assignment and the transactions contemplated hereby shall be paid by the Party which shall have incurred the same and the other Party shall have no liability relating thereto.


14. Third Party Beneficiaries. No person or entity other than the Parties hereto and their respective Affiliates, successors and permitted assigns shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Assignment.

15. No Strict Construction. This Assignment has been prepared jointly and shall not be strictly construed against any Party.

[Signature Page Immediately Follows.]


IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this Assignment as of the Effective Date.

EngMab Beta Holdings LLC

By: 

Name: Sandra Ramos-Alves


Title: Vice President

Bristol-Myers Squibb Company

By: _____

Name: Kimberly M. Jablonski

Title: Vice President


IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this Assignment as of the Effective Date.

EngMab Beta Holdings LLC

By: _____

Name: Sandra Ramos-Alves

Title: Vice President

Bristol-Myers Squibb Company

By:  _____

Name: Kimberly M. Jablonski

Title: Vice President

Annex A to Patent Assignment

Transferred Patents

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Albania	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	AL/P/2016/000476	EngMab Beta Holdings LLC
Albania	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	AL/P/2020/000153	EngMab Beta Holdings LLC
Australia	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	2015299101			10 Dec 2020	2015299101	EngMab Beta Holdings LLC
Australia	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	20 Nov 2020	202027347					EngMab Beta Holdings LLC
Australia	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	2016302881					EngMab Beta Holdings LLC
Australia	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA FOR USE IN TREATMENT OF DISEASES	02 Dec 2015	2015357122	06 Aug 2017	2015357122	09 Sep 2021	2015357122	EngMab Beta Holdings LLC
Australia	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA FOR USE IN TREATMENT OF DISEASES	25 Aug 2021	2021221695					EngMab Beta Holdings LLC
Australia	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	2017353427					EngMab Beta Holdings LLC
Austria	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Austria	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Bahrain	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	20180020					EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Bahrein	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	20190111					EngMab Beta Holdings LLC
Belgium	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14702616.5	16 Dec 2015	2953972	08 Jul 2020	2953972	EngMab Beta Holdings LLC
Belgium	BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA	05 Feb 2014	14705304.5	16 Dec 2015	2953974	20 Dec 2017	2953974	EngMab Beta Holdings LLC
Belgium	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Belgium	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Belgium	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	09 Apr 2014	14715967.7	17 Feb 2016	2984107	19 Jun 2019	2984107	EngMab Beta Holdings LLC
Bosnia and Herzegovina	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Brazil	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	BR112018001955-0	18 Sep 2018	BR112018001955-0	11 May 2021	112018001955-0	EngMab Beta Holdings LLC
Brazil	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	BR112019008426-6	03 Sep 2019	BR112019008426-6			EngMab Beta Holdings LLC
Bulgaria	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Bulgaria	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Canada	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	2995685					EngMab Beta Holdings LLC
Canada	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	2992797					EngMab Beta Holdings LLC
Canada	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA FOR USE IN TREATMENT OF DISEASES	02 Dec 2015	2969560					EngMab Beta Holdings LLC
Canada	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	08 Oct 2015	2963692					EngMab Beta Holdings LLC
Canada	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	3041183					EngMab Beta Holdings LLC
Chile	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	2018-281	09 Nov 2018	281-2018			EngMab Beta Holdings LLC
Chile	MONOCLONAL ANTIBODIES AGAINST BCMA	28 Oct 2020	2020-02801	19 Feb 2021	42885			EngMab Beta Holdings LLC
Chile	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	2019-1198					EngMab Beta Holdings LLC
China	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	201480007526.0	07 Oct 2015	104968683	17 Jul 2020	201480007526.0	EngMab Beta Holdings LLC
China	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	29 Jun 2020	202010603485.9	30 Oct 2020	111848796			EngMab Beta Holdings LLC
China	BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA	05 Feb 2014	201480007525.6	07 Oct 2015	104968682			EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
China	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	201680054839.0	31 Jul 2018	108530073			EngMab Beta Holdings LLC
China	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	201780081998.4	23 Aug 2019	110167964			EngMab Beta Holdings LLC
Colombia	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	NC2018/0001149	10 Jul 2018	832	09 Dec 2019	36695	EngMab Beta Holdings LLC
Croatia	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	P20161211	EngMab Beta Holdings LLC
Croatia	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	P20200390	EngMab Beta Holdings LLC
Cyprus	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	CY1118168	EngMab Beta Holdings LLC
Cyprus	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Czech Republic	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Czech Republic	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Denmark	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14702616.5	16 Dec 2015	2953972	08 Jul 2020	2953972	EngMab Beta Holdings LLC
Denmark	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Denmark	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
EPO	COMBINATION THERAPY FOR CANCER	10 Sep 2021	PCT/EP2021/075012					EngMab Beta Holdings LLC
EPO	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	01 Aug 2019	19189675.2	11 Mar 2020	3620468			EngMab Beta Holdings LLC
EPO	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14702616.5	16 Dec 2015	2953972	08 Jul 2020	2953972	EngMab Beta Holdings LLC
EPO	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2013	13000570.5	06 Aug 2014	2762496			EngMab Beta Holdings LLC
EPO	BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA	05 Feb 2014	14705304.5	16 Dec 2015	2953974	20 Dec 2017	2953974	EngMab Beta Holdings LLC
EPO	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
EPO	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
EPO	MONOCLONAL ANTIBODIES AGAINST BCMA	11 Nov 2019	19208343.4	24 Jun 2020	3670535			EngMab Beta Holdings LLC
EPO	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA FOR USE IN TREATMENT OF DISEASES	02 Dec 2015	15804458.6	11 Oct 2017	3227333			EngMab Beta Holdings LLC
EPO	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA FOR USE IN TREATMENT OF DISEASES	03 Dec 2014	14196168.0	08 Jun 2016	3029068			EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
EPO	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	09 Apr 2014	14715967.7	17 Feb 2016	2984107	19 Jun 2019	2984107	EngMab Beta Holdings LLC
EPO	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	08 Oct 2015	15778294.7	16 Aug 2017	3204415	17 Jun 2020	3204415	EngMab Beta Holdings LLC
EPO	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	17797905.1	11 Sep 2019	3535295			EngMab Beta Holdings LLC
EPO	METHODS OF TREATMENT WITH ANTIBODIES AGAINST BCMA AND CD3	05 Nov 2019	19207293.2					EngMab Beta Holdings LLC
EPO	METHODS OF TREATMENT WITH ANTIBODIES AGAINST BCMA AND CD3	11 Jun 2020	20179573.9					EngMab Beta Holdings LLC
EPO	METHODS OF TREATMENT	05 Nov 2019	19207296.5					EngMab Beta Holdings LLC
EPO	METHODS OF TREATMENT	04 Nov 2020	PCT/US2020/058943					EngMab Beta Holdings LLC
EPO	METHODS OF TREATMENT	29 Apr 2021	PCT/US2021/029877					EngMab Beta Holdings LLC
EPO	METHODS OF TREATMENT	30 Apr 2020	20172322.8					EngMab Beta Holdings LLC
Estonia	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Estonia	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Finland	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	201890441	31 Jul 2018	201890441	21 Jan 2021	036975	EngMab Beta Holdings LLC
Finland	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	201990787	30 Dec 2019	201990787			EngMab Beta Holdings LLC
Finland	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Finland	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
France	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14702616.5	16 Dec 2015	2953972	08 Jul 2020	2953972	EngMab Beta Holdings LLC
France	BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA	05 Feb 2014	14705304.5	16 Dec 2015	2953974	20 Dec 2017	2953974	EngMab Beta Holdings LLC
France	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
France	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
France	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	09 Apr 2014	14715967.7	17 Feb 2016	2984107	19 Jun 2019	2984107	EngMab Beta Holdings LLC
France	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	08 Oct 2015	15778294.7	16 Aug 2017	3204415	17 Jun 2020	3204415	EngMab Beta Holdings LLC
Germany	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14702616.5	16 Dec 2015	2953972	08 Jul 2020	603014067438.0	EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Germany	BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA	05 Feb 2014	14705304.3	16 Dec 2015	2953974	20 Dec 2017	602014018711.0	EngMab Beta Holdings LLC
Germany	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	60201500080.3	EngMab Beta Holdings LLC
Germany	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Germany	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	09 Apr 2014	14715967.7	17 Feb 2016	2984107	19 Jun 2019	602014048589.8	EngMab Beta Holdings LLC
Germany	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	08 Oct 2015	15778294.7	16 Aug 2017	3204415	17 Jun 2020	602015054418.8	EngMab Beta Holdings LLC
Greece	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	3090150	EngMab Beta Holdings LLC
Greece	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Hong Kong	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	16100577.3	17 Jun 2016	1212710	01 Apr 2021	1212710	EngMab Beta Holdings LLC
Hong Kong	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	18 Aug 2020	42020014169.5	11 Dec 2020	40024249			EngMab Beta Holdings LLC
Hong Kong	BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA	05 Feb 2014	16100575.5	17 Jun 2016	1212709	21 Sep 2018	HK1212709	EngMab Beta Holdings LLC
Hong Kong	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	02 Jun 2016	16106248.9	10 Feb 2017	1218299	08 Dec 2017	HK1218299	EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Hong Kong	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Jul 2018	18108543.5	26 Oct 2018	1249114	04 Sep 2020	1249114	EngMab Beta Holdings LLC
Hong Kong	MONOCLONAL ANTIBODIES AGAINST BCMA	25 Nov 2020	42020020684.5	12 Mar 2021	40031329			EngMab Beta Holdings LLC
Hong Kong	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA FOR USE IN TREATMENT OF DISEASES	20 Mar 2018	18103837.1	10 Aug 2018	1244491			EngMab Beta Holdings LLC
Hong Kong	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	16 Sep 2019	19129662.3	15 May 2020	40006116			EngMab Beta Holdings LLC
Hungary	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Hungary	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Iceland	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Iceland	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
India	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	201827002347	04 May 2018	201827002347			EngMab Beta Holdings LLC
Ireland	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14702616.5	16 Dec 2015	2953972	08 Jul 2020	2953972	EngMab Beta Holdings LLC
Ireland	BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA	05 Feb 2014	14705304.5	16 Dec 2015	2953974	20 Dec 2017	2953974	EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Ireland	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Ireland	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Ireland	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	09 Apr 2014	14715967.7	17 Feb 2016	2984107	19 Jun 2019	2984107	EngMab Beta Holdings LLC
Israel	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	257233	29 Mar 2018	257233	01 Oct 2021	257233	EngMab Beta Holdings LLC
Israel	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	266424	30 Jun 2019	266424			EngMab Beta Holdings LLC
Italy	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14702616.5	16 Dec 2015	2953972	08 Jul 2020	502010000104449	EngMab Beta Holdings LLC
Italy	BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA	05 Feb 2014	14705304.5	16 Dec 2015	2953974	20 Dec 2017	502018000009576	EngMab Beta Holdings LLC
Italy	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	5020160000095272	EngMab Beta Holdings LLC
Italy	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Italy	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	09 Apr 2014	14715967.7	17 Feb 2016	2984107	19 Jun 2019	502019000072290	EngMab Beta Holdings LLC
Italy	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	08 Oct 2015	15778294.7	16 Aug 2017	3204415	17 Jun 2020	3204415	EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Japan	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	2015-555751	22 Mar 2016	2016-508496	27 Dec 2019	6656803	EngMab Beta Holdings LLC
Japan	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	03 Oct 2019	2019-183002	13 Feb 2020	2020-23323	26 Jul 2021	6918065	EngMab Beta Holdings LLC
Japan	BISPECIFIC ANTIBODIES AGAINST CD137SILON AND BCMA	27 Jul 2020	2020-126460	05 Nov 2020	2020-180158	14 Sep 2021	6944573	EngMab Beta Holdings LLC
Japan	BISPECIFIC ANTIBODIES AGAINST CD137SILON AND BCMA	03 Aug 2015	2017-505793	02 Nov 2017	2017-532290	12 May 2020	6703520	EngMab Beta Holdings LLC
Japan	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	2018-526303	08 Nov 2018	2018-532766	27 Mar 2020	6682632	EngMab Beta Holdings LLC
Japan	MONOCLONAL ANTIBODIES AGAINST BCMA	25 Mar 2020	2020-054175	16 Jul 2020	2020-109117	24 Jun 2021	6903188	EngMab Beta Holdings LLC
Japan	BISPECIFIC ANTIBODIES AGAINST CD137SILON AND BCMA FOR USE IN TREATMENT OF DISEASES	02 Dec 2015	2017-529637	29 Mar 2018	2018-508462			EngMab Beta Holdings LLC
Japan	BISPECIFIC ANTIBODIES AGAINST CD137SILON AND BCMA FOR USE IN TREATMENT OF DISEASES	15 Apr 2021	2021-069083	19 Aug 2021	2021-120374			EngMab Beta Holdings LLC
Japan	BISPECIFIC ANTIBODIES AGAINST CD137SILON and ROR1	08 Oct 2015	2017-518525	25 Jan 2018	2018-502050	25 May 2020	6708635	EngMab Beta Holdings LLC
Japan	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	2019-523769	09 Jan 2020	2020-500181			EngMab Beta Holdings LLC
Korea	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	10-2018-7005941	25 Apr 2018	10-2018-0042271			EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Korea	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	10-2019-7015708					EngMab Beta Holdings LLC
Kuwait	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	KW/P/2019/000147					EngMab Beta Holdings LLC
Latvia	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Latvia	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Lithuania	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Lithuania	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Luxembourg	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Luxembourg	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Macedonia	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	MK/P/2016/640	EngMab Beta Holdings LLC
Macedonia	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	MK/P/2020/180	EngMab Beta Holdings LLC
Malta	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Malta	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Mexico	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	MX/a/2018/001398			27 Nov 2020		EngMab Beta Holdings LLC
Mexico	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	MX/a/2019/004621					EngMab Beta Holdings LLC
Morocco	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Morocco	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Montenegro	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Morocco	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	39266	EngMab Beta Holdings LLC
Netherlands	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14702616.5	16 Dec 2015	2953972	08 Jul 2020	2953972	EngMab Beta Holdings LLC
Netherlands	BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA	05 Feb 2014	14705304.5	16 Dec 2015	2953974	20 Dec 2017	2953974	EngMab Beta Holdings LLC
Netherlands	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Netherlands	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Netherlands	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	09 Apr 2014	14715967.7	17 Feb 2016	2984107	19 Jun 2019	2984107	EngMab Beta Holdings LLC
New Zealand	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	728534					EngMab Beta Holdings LLC
New Zealand	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	31 Jul 2020	766724					EngMab Beta Holdings LLC
New Zealand	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	739252					EngMab Beta Holdings LLC
New Zealand	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	752777					EngMab Beta Holdings LLC
Norway	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14702616.5	16 Dec 2015	2953972	08 Jul 2020	2953972	EngMab Beta Holdings LLC
Norway	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Norway	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Oman	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	OM/P/2018/00022					EngMab Beta Holdings LLC
Oman	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	OM/P/2019/00181					EngMab Beta Holdings LLC
Poland	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14702616.5	16 Dec 2015	2953972	08 Jul 2020	2953972	EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Poland	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Poland	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Portugal	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Portugal	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Qatar	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	QA/201801/00046					EngMab Beta Holdings LLC
Qatar	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	QA/201905/00237					EngMab Beta Holdings LLC
Romania	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Romania	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Russia	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	201890441	31 Jul 2018	201890441	21 Jan 2021	036975	EngMab Beta Holdings LLC
San Marino	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	SM-T-201600392	EngMab Beta Holdings LLC
San Marino	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	SM-T-202000139	EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Saudi Arabia	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	518390854			12 Jul 2020	7329	EngMab Beta Holdings LLC
Saudi Arabia	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	519401706					EngMab Beta Holdings LLC
Serbia	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	55410	EngMab Beta Holdings LLC
Serbia	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	P-2020/0276	EngMab Beta Holdings LLC
Singapore	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	11201700551T			23 Dec 2020	11201700551T	EngMab Beta Holdings LLC
Singapore	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	11201800487Y	27 Feb 2018	11201800487Y	28 Oct 2020	11201800487	EngMab Beta Holdings LLC
Singapore	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	11201903359R					EngMab Beta Holdings LLC
Slovakia	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Slovakia	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Slovenia	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Slovenia	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
South Africa	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	2018/00435			19 Dec 2018	2018/00435	EngMab Beta Holdings LLC
South Africa	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	2019/02366					EngMab Beta Holdings LLC
Spain	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14702616.5	16 Dec 2015	2953972	08 Jul 2020	2953972	EngMab Beta Holdings LLC
Spain	BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA	05 Feb 2014	14705304.5	16 Dec 2015	2953974	20 Dec 2017	2953974	EngMab Beta Holdings LLC
Spain	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Spain	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Spain	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	09 Apr 2014	14715967.7	17 Feb 2016	2984107	19 Jun 2019	2984107	EngMab Beta Holdings LLC
Spain	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	08 Oct 2015	15778294.7	16 Aug 2017	3204415	17 Jun 2020	3204415	EngMab Beta Holdings LLC
Sweden	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14702616.5	16 Dec 2015	2953972	08 Jul 2020	2953972	EngMab Beta Holdings LLC
Sweden	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Sweden	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
Switzerland	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14702616.5	16 Dec 2015	2953972	08 Jul 2020	2953972	EngMab Beta Holdings LLC
Switzerland	BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA	05 Feb 2014	14705304.5	16 Dec 2015	2953974	20 Dec 2017	2953974	EngMab Beta Holdings LLC
Switzerland	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
Switzerland	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
Switzerland								
Switzerland	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	09 Apr 2014	14715967.7	17 Feb 2016	2984107	19 Jun 2019	2984107	EngMab Beta Holdings LLC
Thailand	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	1801000653					EngMab Beta Holdings LLC
Thailand	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	1901002626					EngMab Beta Holdings LLC
Turkey	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2016/13075	EngMab Beta Holdings LLC
Turkey	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	TR20200364174	EngMab Beta Holdings LLC
United Arab Emirates	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	Pe0000192/18					EngMab Beta Holdings LLC
United Arab Emirates	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	Pe0000645/19					EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
United Kingdom	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14702616.5	16 Dec 2015	2953972	08 Jul 2020	2953972	EngMab Beta Holdings LLC
United Kingdom	BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA	05 Feb 2014	14705304.5	16 Dec 2015	2953974	20 Dec 2017	2953974	EngMab Beta Holdings LLC
United Kingdom	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15179545.7	10 Feb 2016	2982694	22 Jun 2016	2982694	EngMab Beta Holdings LLC
United Kingdom	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	16750150.1	13 Jun 2018	3331910	11 Dec 2019	3331910	EngMab Beta Holdings LLC
United Kingdom	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	09 Apr 2014	14715967.7	17 Feb 2016	2984107	19 Jun 2019	2984107	EngMab Beta Holdings LLC
United Kingdom	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	08 Oct 2015	15778294.7	16 Aug 2017	3204415	17 Jun 2020	3204415	EngMab Beta Holdings LLC
United States	COMBINATION THERAPY FOR CANCER	11 Sep 2020	631077233					EngMab Beta Holdings LLC
United States	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	04 Nov 2020	171089433					EngMab Beta Holdings LLC
United States	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	04 Apr 2018	151945554	09 Aug 2018	2018-0222991	01 Dec 2020	10851171	EngMab Beta Holdings LLC
United States	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	14764967	24 Dec 2015	2015-0368351	08 May 2018	9963513	EngMab Beta Holdings LLC
United States	BISPECIFIC ANTIBODIES AGAINST CD3 AND BCMA	05 Feb 2014	14764968	31 Dec 2015	2015-0376287	18 Sep 2018	10077315	EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
United States	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA	03 Aug 2015	15/501620	26 Oct 2017	2017-0306036	09 Apr 2019	10253104	EngMab Beta Holdings LLC
United States	MONOCLONAL ANTIBODIES AGAINST BCMA	03 Aug 2016	15/747385	21 Nov 2019	2019-0352427			EngMab Beta Holdings LLC
United States	MONOCLONAL ANTIBODIES AGAINST BCMA	17 Mar 2020	16/821895					EngMab Beta Holdings LLC
United States	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA FOR USE IN TREATMENT OF DISEASES	19 Aug 2020	16/997565					EngMab Beta Holdings LLC
United States	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	27 Jan 2020	16/773927					EngMab Beta Holdings LLC
United States	BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1	08 Oct 2015	15/517296	26 Oct 2017	2017-0306018			EngMab Beta Holdings LLC
United States	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	02 Nov 2017	16/346771	29 Aug 2019	2019-0263920	21 Sep 2021	111124577	EngMab Beta Holdings LLC
United States	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	24 Jun 2021	17/304683					EngMab Beta Holdings LLC
United States	BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA	24 Jun 2021	17/304702					EngMab Beta Holdings LLC
United States	ANTI-BCMA THERAPY AUTOMATINE DISORDERS	12 Feb 2020	62/975663					EngMab Beta Holdings LLC
WO	COMBINATION THERAPY FOR CANCER	10 Sep 2021	PCT/EP2021/075012					EngMab Beta Holdings LLC

Country	Title	Filing Date	Filing Number	Publication Date	Publication Number	Grant Date	Grant Number	Owner
WO	METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA	05 Feb 2014	PCT/EP2014/052189	14 Aug 2014	2014-122143			EngMab Beta Holdings LLC
WO	BISPECIFIC ANTIBODIES AGAINST CD38 AND BCMA FOR USE IN TREATMENT OF DISEASES	02 Dec 2015	PCT/EP2015/078388	09 Jun 2016	2016-087531			EngMab Beta Holdings LLC
WO	METHODS OF TREATMENT WITH ANTIBODIES AGAINST BCMA AND CD3	04 Nov 2020	PCT/US2020/058939	14 May 2021	WO2021/092056			EngMab Beta Holdings LLC
WO	METHODS OF TREATMENT	04 Nov 2020	PCT/US2020/058943	14 May 2021	WO2021/092060			EngMab Beta Holdings LLC
WO	METHODS OF TREATMENT	29 Apr 2021	PCT/US2021/029877	04 Nov 2021	WO2021/222552			EngMab Beta Holdings LLC
WO	ANTI-BCMA THERAPY AUTOIMMUNE DISORDERS	11 Feb 2021	PCT/US2021/017665	19 Aug 2021	WO2021/163329			EngMab Beta Holdings LLC

PATENT

REEL: 063353 FRAME: 0638

RECORDED: 04/17/2023